Skip to main content
Midas Edge

Fortress Biotech, Inc.

For the period ended Dec 31, 2024. Filed Mar 31, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 31, 2025

FBIO$1.91-4.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Consolidated Statements of Changes in Stockholders’ Equity

For the Year Ended December 31, 2024

​​​​​​​​​​​​​​​​​​​​​​​​​​
​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · Common · ​ · Additional · ​ · ​ · ​ · ​ · ​ · ​ · ​ · Total
​ · ​ · Series A Preferred Stock · ​ · Common Stock · ​ · Shares · ​ · Paid-In · ​ · Accumulated · ​ · Non-Controlling · ​ · Stockholders'
($ in thousands except for share amounts) · Shares · ​ · Shares · Amount · Issuable · Capital · Deficit · Interests · Equity
Balance at December 31, 20233,427,138​$315,093,053​$15​$—​$717,396​$(694,870)​$(20,957)​$1,587
Stock-based compensation expense—​——​—​—​32,619​—​—​32,619
Issuance of common stock related to equity plans—​—582,323​1​—​(1)​—​—​—
Issuance of common stock under ESPP—​—69,482​—​—​99​—​—​99
Issuance of stock for equity offerings, net​—​—8,006,058​8​—​17,396​—​—​17,404
Warrant issued in conjunction with debt​​​​​​​​​​​​​​​1,104​​​​​​​​1,104
Issuance of common stock for at-the-market offering, net—​—1,957,331​2​—​3,732​—​—​3,734
Common shares issued for dividend on partner company's convertible preferred shares​—​—64,747​—​—​114​—​—​114
Common shares issued for exchange of partner company's convertible preferred shares​—​—2,028,345​2​—​3,406​—​—​3,408
Warrants issued in conjunction with exchange of partner company's convertible preferred shares​​​​​​​​​​​​​​​341​​​​​​​​341
Preferred A dividends declared and paid—​——​—​—​(4,016)​—​—​(4,016)
Partner companies’ offerings, net—​—​​—​—​28,852​—​—​28,852
Partner companies' at-the-market offering, net—​——​—​—​12,037​—​—​12,037
Issuance of common stock under partner company’s ESPP—​——​—​—​257​—​—​257
Partner company’s dividends declared and paid—​——​—​—​(694)​—​—​(694)
Exercise of warrants for cash—​—107,500​—​—​181​—​—​181
Exercise of partner company options and warrants for cash, net—​——​—​—​22,184​—​—​22,184
Non-controlling interest in subsidiaries—​——​—​—​(71,434)​—​71,434​—
Net loss attributable to non-controlling interest—​——​—​—​—​—​(74,858)​(74,858)
Net loss attributable to common stockholders—​——​—​—​—​(45,997)​—​(45,997)
Balance at December 31, 2024​3,427,138​$327,908,839​$28​$—​$763,573​$(740,867)​$(24,381)​$(1,644)

Consolidated Statements of Changes in Stockholders’ Equity

For the Year Ended December 31, 2023

​​​​​​​​​​​​​​​​​​​​​​​​​​
​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · Common · ​ · Additional · ​ · ​ · ​ · ​ · ​ · ​ · ​ · Total
​ · ​ · Series A Preferred Stock · ​ · Common Stock · ​ · Shares · ​ · Paid-In · ​ · Accumulated · ​ · Non-Controlling · ​ · Stockholders'
($ in thousands except for share amounts) · Shares · ​ · Shares · Amount · Issuable · Capital · Deficit · Interests · Equity
Balance at December 31, 20223,427,138​$37,366,283​$7​$—`$675,944​$(634,233)​$8,304​$50,025
Stock-based compensation expense—​——​—​—​17,029​—​—​17,029
Issuance of common stock related to equity plans—​—224,690​—​—​—​—​—​—
Issuance of stock for public offerings, net​—​—6,994,526​7​—​22,078​—​—​22,085
Issuance of common stock for at-the-market offering, net—​—224,003​—​—​2,041​—​—​2,041
Warrant charge in conjunction with Oaktree debt​​​​​​​​​​​​​​​272​​​​​​​​272
Common shares issued for dividend on partner company's convertible preferred shares​—​—58,551​—​—​266​—​—​266
Payment of Series A perpetual preferred stock dividends—​——​—​—​(8,032)​—​—​(8,032)
Exercise of warrants for cash—​—225,000​1​—​382​—​—​383
Partner companies’ proceeds from stock and warrants, net—​—​​—​—​59,956​—​—​59,956
Partner companies' at-the-market offering, net—​——​—​—​4,620​—​—​4,620
Partner company’s exercise of options for cash—​——​—​—​121​—​—​121
Issuance of common stock under partner company’s ESPP—​——​—​—​178​—​—​178
Partner company’s dividends declared and paid—​——​—​—​(736)​—​—​(736)
Partner company’s redemption of preferred shares—​——​—​—​(400)​—​—​(400)
Issuance of partner company’s common shares for research and development expenses—​——​—​—​1,240​—​—​1,240
Deconsolidation/dissolution of partner companies—​——​—​—​—​—​6,693​6,693
Non-controlling interest in subsidiaries—​——​—​—​(57,563)​—​57,563​—
Net loss attributable to non-controlling interest—​——​—​—​—​—​(93,517)​(93,517)
Net loss attributable to common stockholders—​——​—​—​—​(60,637)​—​(60,637)
Balance at December 31, 2023​3,427,138​$315,093,053​$15​$—​$717,396​$(694,870)​$(20,957)​$1,587
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.